De Luca G, Verdoia M, Savonitto S, et al. - Among participants (n = 1,408) of the Elderly-ACS 2 trial—which is a randomized, open-label, blinded endpoint research comparing low-dose (5mg) prasugrel vs clopidogrel among elderly acute coronary syndrome (ACS) patients—researchers assessed the prognostic influence of body mass index (BMI) on the clinical result. At admission, BMI was measured. Cardiovascular (CV) mortality was the primary endpoint of this study. Based on median values of BMI (< or ≥ 25.7 Kg/m²), groups of patients were defined. A median follow-up of 367 days was performed which revealed no influence of BMI on CV mortality in the overall population. According to the findings, the survival or the risk of major cardiovascular and bleeding complications was not conditioned by BMI among elderly patients experiencing ACS. Consistency of the findings was seen across various patient risk categories.